Hua Medicine taps Hong Kong for biotech flotation
Hua Medicine has filed for an IPO in Hong Kong under sponsors CLSA and Goldman Sachs, as the promised pipeline of biotechnology issuers begins to materialise following the city’s new listing rules.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: